Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults
NCT06885021Phase 3Not yet recruiting
- Sponsor
- Huadong Medicine
- Start
- Mar 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of conveglipron in obesity and Overweight (3 arms), sponsored by Huadong Medicine. Primary endpoints: Percentage Change From Baseline in Body Weight at 44 weeks and Percentage Change of Participants Achieving Weight Loss ≥ 5% at 44 weeks. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
conveglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06885021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06885021.